-
Abstract Number: PB0630
Early Systemic Administration of a Natural Carboxypeptidase Inhibitor Potentiates tPA-mediated Thrombolysis: Evidence from Real-time Intravital Imaging Analysis of Microthrombi in Mice
-
Abstract Number: PB0792
Early use of eculizumab in patient with pregnancy-associated atypical haemolytic-uraemic syndrome
-
Abstract Number: PB0705
East Texas Bleeding Disorder – A Novel Bleeding Disorder
-
Abstract Number: VPB1193
Easy and efficient method for purification of human thrombin, for use as a component of fibrin sealants.
-
Abstract Number: VPB1423
Easy clot characteristics of the placenta in a case of congenital hypofibrinogenemia．
-
Abstract Number: PB0497
Educational intervention effectiveness evaluated with time in therapeutic range in patients with atrial fibrillation and low educational level and social vulnerability in Corrientes Argentina
-
Abstract Number: PB1013
Educational Resources on Periprocedural Anticoagulation Management: A Systematic Review
-
Abstract Number: PB0858
Effect of Agonist Stimulation and Antiplatelet Drugs on Platelet Contractility
-
Abstract Number: PB1206
Effect of agonists to thrombopoietin receptors on platelet glycome of patients with immune thrombocytopenia
-
Abstract Number: PB1079
Effect of anti -factor Xa direct oral anticoagulants (DOACs) on viscoelasticity measurements in External Quality Assessment (EQA) samples: UK NEQAS BC experience
-
Abstract Number: PB1207
Effect Of Anti-Nuclear Antibody Positivity On Adult Newly Diagnosed Immune Thrombocytopenia Prognosis.
-
Abstract Number: PB1238
Effect of constitutive activation of the calcium sensor STIM1 on haemostasis
-
Abstract Number: PB1214
Effect of eltrombopag on platelet receptor expression and activation in patients with immune thrombocytopenia
-
Abstract Number: OC 21.4
Effect of Growth on AAV-mediated Expression of FIX-R338L in Juvenile Hemophilia B Dogs
-
Abstract Number: VPB0342
Effect of high molecular weight polyethylene oxide on thrombosis under high shear blood flow conditions
-
Abstract Number: PB0644
Effect of Novel Thrombolytic Aptamer DTRI-031 on Microfluidic Thrombolysis and VWF Function Dose-Response
-
Abstract Number: PB0688
Effect of PK Assessment on clinical outcomes for patients with moderate to severe Hemophilia A
-
Abstract Number: PO0049
Effect of platelet-rich plasma in combination with autologous adipose- derived mesenchymal stem cell in treatment of calcaneal enthesophytes.
-
Abstract Number: PB0274
Effect of SARS-CoV-2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease
-
Abstract Number: OC 64.5
Effect of the DIAPH1 R1213* GOF variant in actin-dependent cytoskeleton organization in megakaryocytes
-
Abstract Number: PB0557
Effectiveness and safety of Direct Oral Anticoagulants (DOACs) in extremely obese compared to non-extremely obese patients in an observational prospective single-centre unselected patient registry
-
Abstract Number: OC 62.1
Effectiveness and safety of direct oral anticoagulants among octogenarians with venous thromboembolism: an international multi-database cohort study
-
Abstract Number: OC 71.4
Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY
-
Abstract Number: PB1358
Effectiveness of an electronic decision support system for management of venous thromboembolism in hospitalized patients
-
Abstract Number: PB1017
Effectivity of Andexanet Alfa for the Reversal of Factor Xa Inhibitors under Hemodilution
-
Abstract Number: OC 17.4
Effects of andexanet alfa on different thrombin generation and anti-Xa-methods in vitro.
-
Abstract Number: PB0254
Effects of apixaban versus vitamin K antagonists and low molecular weight heparin in pediatric cardiac patients: exploratory biomarker analysis from SAXOPHONE a multicentre randomized clinical trial
-
Abstract Number: VPB0638
Effects of Clot Contraction on Clot Degradation: A Mathematical and Experimental Approach
-
Abstract Number: OC 51.5
Effects of gender and hormonal status on thrombin generation in a large population-based cohort of twins and their family members
-
Abstract Number: PB0689
Effects of PK Assessment on FVIII Consumption and Estimated Costs for patients with moderate to severe Hemophilia A
-
Abstract Number: OC 22.3
Effects of platelet-inspired haemostatic nanoparticles on bleeding in von Willebrand disease murine models
-
Abstract Number: VPB0901
Effects of platelets activated by different agonists on fibrin formation and thrombin generation.
-
Abstract Number: PB0439
Efficacy and safety of apixaban versus warfarin in Morbid obese patients with venous thromboembolism.
-
Abstract Number: PB1188
Efficacy and safety of eptacog beta for resolution of spontaneous versus traumatic bleeding episodes in patients with hemophilia A or B with inhibitors
-
Abstract Number: VPB1375
Efficacy and safety of extended thromboprophylaxis with Apixaban after endovenous ablation for varicose veins in patients with a history of thrombophlebitis and venous thromboembolism
-
Abstract Number: PB0545
Efficacy and safety of Haemocer, a local hemostatic agent, in patients with congenital bleeding disorders: A pilot study
-
Abstract Number: PB1356
Efficacy and safety of prophylactic anticoagulation in adult and children patients with primary nephrotic syndrome: a systematic review and meta-analysis
-
Abstract Number: PB0986
Efficacy and safety of prothrombin complex concentrate for major bleeding in patients treated with direct Factor-Xa inhibitors
-
Abstract Number: VPB0318
Efficacy and safety of single, low-dose rituximab-contained regimen for Refractory/Relapsed thrombotic thrombocytopenic purpura: a retrospective study of 7 cases
-
Abstract Number: VPB0319
Efficacy and safety of two different low-dose rituximab regimens for Chinese children patients with primary immune thrombocytopenia
-
Abstract Number: VPB0117
Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis
-
Abstract Number: PB0338
Efficacy comparison and safety analysis of megadose recombinant human thrombopoietin(rhTPO) in the treatment of immune thrombocytopenia (ITP)
-
Abstract Number: OC 30.2
Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Real-life-data documented by eDiary smart medication
-
Abstract Number: PB1027
Efficacy of haemodialysis in the long-lasting elimination of dabigatran
-
Abstract Number: PB0255
Efficacy of normal saline versus heparin locking in the prevention of non-valved peripherally inserted central catheter associated complications: a systematic review
-
Abstract Number: PB1179
Efficacy of subcutaneous versus intravenous administration of desmopressin in patients with von Willebrand disease and hemophilia A in need of COVID-19 vaccination
-
Abstract Number: PB0215
Efficacy, effectiveness, and safety of emicizumab for the treatment of people with hemophilia A: a systematic review
-
Abstract Number: PB0216
Efficacy, effectiveness, and safety of extended half-life factor VIII products for the treatment of hemophilia A: protocol of a systematic review
-
Abstract Number: VPB0697
Efficacy, Safety and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (SCT800) in Previously Treated Children with Severe Hemophilia A.
-
Abstract Number: OC 40.2
Efficacy, Safety, and Pharmacokinetics of Emicizumab Prophylaxis in Patients with Acquired Hemophilia A: Primary Analysis Results from a Phase III Study (AGEHA)
-
Abstract Number: LB 01.4
Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study
-
Abstract Number: PB0347
Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases
-
Abstract Number: VPB1190
Efmoroctocog alfa and invasive procedures in patients with hemophilia A
-
Abstract Number: VPB0504
Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation
-
Abstract Number: PB0013
Elevated Activated Partial Thromboplastin Time-based Clot Waveform Analysis Parameters are Associated with Acute Myocardial Infarction and its Adverse Outcomes
-
Abstract Number: PB0582
Elevated contact pathway activity in patients with acute venous thromboembolism
-
Abstract Number: PB1296
Elevated NET-Formation and Citrullinated-Fibrinogen are Found in a Porcine Model of Acute Limb Ischemia Reperfusion Injury
-
Abstract Number: OC 01.3
Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy
-
Abstract Number: PB0402
Elucidation of Specific Platelet Signaling Pathways Perturbed in SLFN14-Mutated Patients with Inherited Macrothrombocytopenia and Bleeding
-
Abstract Number: PB0817
Emicizumab ameliorates hemostasis in von Willebrand Disease type 3 but not type 2A murine models
-
Abstract Number: PB0002
Emicizumab for the treatment of acquired hemophilia A: an update of the Vienna experience
-
Abstract Number: PB0661
Emicizumab in haemophilia A with inhibitors and end-stage renal disease
-
Abstract Number: OC 30.5
Emicizumab Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study
-
Abstract Number: OC 30.1
Emicizumab prophylaxis in people with severe haemophilia A without inhibitors: outcomes from the UK Haemophilia Centre Doctors’ Organisation
-
Abstract Number: PO0035
Emicizumab prophylaxis: experience of a single center.
-
Abstract Number: OC 30.4
Emicizumab real world experience using the entire-vial based dosing regimen in for patients with haemophilia A: AN UPDATE
-
Abstract Number: VPB0230
Emicizumab treatment of 4 patients with severe hemophilia A and inhibitors in pediatric age – Resource management to minimize economic costs while maintaining the quality of clinical follow-up
-
Abstract Number: PB0167
Emicizumab use in Acquired von Willebrand Disease: Single Case Report
-
Abstract Number: PB0229
Emicizumab: In-house method validation
-
Abstract Number: VPB0022
Emodin- Mediated Pulsed Focused Ultrasound Sonodynamic Therapy of Early Stage Atherosclerosis in The Rabbit Common Carotid Artery
-
Abstract Number: PB0889
Endogenous nitroxyl (HNO) production in a normal biological system and its role in platelet function.
-
Abstract Number: PB0977
Endogenous thrombin generation potential in patients with pulmonary embolism and its relevance to thrombo-inflammatory biomarkers.
-
Abstract Number: PB0444
Endoscopic Evaluation in Patients with Gastrointestinal Bleeding Receiving Anticoagulation for Venous Thromboembolism
-
Abstract Number: OC 05.5
Endothelial cell activation, Weibel-Palade body secretion and enhanced angiogenesis in severe COVID-19
-
Abstract Number: PB1267
Endothelial damage biomarkers panel to predict response to extracorporeal photopheresis in steroid refractory acute GVHD patients
-
Abstract Number: OC 56.3
Endothelial Overexpression of Transforming Growth Factor Beta Induced in Chronic Thromboembolic Pulmonary Hypertension
-
Abstract Number: PB1283
Endothelial P2X7 promotes venous thromboembolism
-
Abstract Number: OC 68.2
Endothelial Toll-like receptor 4 regulates arterial thrombus growth
-
Abstract Number: PB0401
Endothelial-induced regulation of platelet signalling under flow: establishing the endothelial-controlled platelet phosphoproteome
-
Abstract Number: OC 45.5
Endothelial-targeted recombinant CD39 as novel therapy for brain ischaemia
-
Abstract Number: VPB0692
Enhanced pharmacokinetics and improved clinical outcomes in young hemophiliac boys after the switch to BAY 81-8973 from other standard half-life FVIII concentrates
-
Abstract Number: PB0538
Enzymatic activity of bound thrombin within fibrin fibers
-
Abstract Number: PB1299
EPCR−PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia via mechanism involving nitric oxide
-
Abstract Number: PB0913
Epidemiology of asymptomatic venous thrombotic events in pediatric cancer patients: A population-based study from Canada
-
Abstract Number: OC 58.5
Epigenetic regulation of endothelial dysfunction in thromboembolic venous disease
-
Abstract Number: PB1174
Eptacog beta for resolution of bleeding episodes in patients with hemophilia A or B with inhibitors: Efficacy and safety according to inhibitor titer
-
Abstract Number: VPB1166
Eradication of FIX inhibitor in haemophilia B children: A retrospective study from haemophilia pediatric comprehensive care center of China
-
Abstract Number: PB1270
Erythrocyte Components Affect Vascular Calcification By Modulating Nitric Oxide Signaling At Sites Of Intramural Microhemorrhage
-
Abstract Number: VPB0430
Erythrocyte-derived microvesicles and microRNA-144/451 cluster in patients with post-thromboembolic syndrome
-
Abstract Number: PB1030
Erythrocytes impair the anticoagulant function of the protein C system in whole blood thrombin generation.
-
Abstract Number: PO0017
Essential Biomarkers for a Clinical Study of a Novel Allogeneic Cell Therapy for Acute Graft-versus-Host Disease
-
Abstract Number: PB0766
Essential oils and their sesquiterpenes reduce DENV-2-induced platelet activation
-
Abstract Number: PB0407
Establishing the signalling pathways regulating reversible platelet integrin activation
-
Abstract Number: PB0179
Establishment of a monolayer-based LSEC-like endothelial cell in vitro system from induced pluripotent stem cells
-
Abstract Number: VPB1122
Establishment of Reference Intervals for Prothrombin Time and International Normalized Ratio in Pakistani Children using an Indirect Data Mining Approach
-
Abstract Number: PB0320
Estimation of prevalence and factors affecting Aspirin / Clopidogrel resistance in Indian patients evaluated by light transmission aggregometry and VerifyNow
-
Abstract Number: VPB0680
Evaluating factors that influence the joint health status of Nigerians with moderate and severe Haemophilia (WBDR Research Support Program )
-
Abstract Number: PB1324
Evaluating routine data sources and efficient methods to determine the incidence of venous thromboembolism and major bleeding in unselected medical and surgical inpatients.
-
Abstract Number: PB1394
Evaluating the haemostatic changes in pregnancy via global coagulation assays: A series of 27 pregnant females in the first trimester
-
Abstract Number: PB1409
Evaluating the Haemostatic Effects of Tranexamic Acid in Women with Preeclampsia: an Experimental Ex Vivo Study
-
Abstract Number: PB0050
Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients
-
Abstract Number: PB1306
Evaluation of a LAMP assay for detection of Prothrombin Allele and Factor V Leiden
-
Abstract Number: PB0292
Evaluation of a Rapid Screening Test as an Effective Tool in Decentralizing ADAMTS13 Activity Testing – Report from the Rapid Assessment of Plasma in Microangiopathic Thrombocytopenia (RAPMAT) study
-
Abstract Number: PB0912
Evaluation of activated protein C resistance in women undergoing tamoxifen therapy: pilot study
-
Abstract Number: PB1077
Evaluation of Automated Mixing Studies and Calculation of Index of Circulating Anticoagulant in Samples with Lupus Anticoagulant or Factor VIII Inhibitors
-
Abstract Number: PB0103
Evaluation of Changes in Antiphospholipid Antibody Titers Following Vaccination with SARS-CoV-2 mRNA in Patients with Autoimmune Diseases
-
Abstract Number: VPB0121
EVALUATION OF CLOT WAVEFORM PATTERNS IN CoVID-19 PATIENTS
-
Abstract Number: VPB0133
Evaluation of D-dimer Concentrations Measured With Three Methods in Patients With COVID-19
-
Abstract Number: PB0460
Evaluation of edoxaban plasma concentration data from clinical practice.
-
Abstract Number: PB0220
Evaluation of four different reagents on the coagulation analyzers STAR MAX® and ATELLICA® COAG 360 for Emicizumab concentration measurement in severe hemophilia A patients
-
Abstract Number: VPB0252
Evaluation of guidelines for primary immune thrombocytopenia
-
Abstract Number: VPB1430
Evaluation of hemostasis disorders and the level of neutrophil extracellular traps in pregnant women with thrombophilia
-
Abstract Number: PB0526
Evaluation of intracerebral haematoma expansion of the new oral anticoagulants in rats.
-
Abstract Number: VPB0113
Evaluation of intravascular coagulation in patients with COVID-19 pneumonia.
-
Abstract Number: PB1056
Evaluation of Neutrophil Lymphocytes Ratio and Platelets Lymphocytes Ratio in Immune thrombocytopenic purpura
-
Abstract Number: PB1170
Evaluation of nonacog beta pegol recovery in spiked samples using different APTT reagents/detection system available in Argentina.
-
Abstract Number: OC 14.4
Evaluation of patients’ experience and related qualitative outcomes in venous thromboembolism: A scoping review
-
Abstract Number: PB0700
Evaluation of Pharmacological Enhancers of Mutated Factor VII Activity ex vivo
-
Abstract Number: PB1054
Evaluation of platelet function in rare or undiagnosed bleeding disorders
-
Abstract Number: PB0815
Evaluation of the diagnostic accuracy of VWF:Ac and VWF Ristocetin Cofactor Activity in the diagnosis of von Willebrand disease
-
Abstract Number: PB1089
Evaluation of the effect of freezing and thawing of citrated plasma on coagulation assays
-
Abstract Number: VPB0569
Evaluation of the FibWave in Edoxaban and Healthy Samples, a Comparison with the APTT- and PT-based Clot Waveform Analysis
-
Abstract Number: PB0854
Evaluation of the hemostatic ability of the new device Total Thrombus Formation Analysis System’ (T-TAS) for thrombocytopenic patients. In vitro effect of Thrombosomes®
-
Abstract Number: PB1413
Evaluation of the qLabs FIB system, a novel rapid and easy-to-use point-of-care system to quantify functional fibrinogen level using a single drop of citrated whole blood sample.
-
Abstract Number: PB1072
Evaluation of the ultrasound sonorheometry based Quantra® System to monitor hemostasis in patients undergoing plasma exchange therapy
-
Abstract Number: VPB0004
Evaluation of the utility of BAT (ISTH-SSC bleeding assessment tool) questionnaire in the diagnostic of acquired von Willebrand syndrome
-
Abstract Number: VPB1048
Evaluation of thrombin burst using thrombin time of clot waveform analysis
-
Abstract Number: PB0224
Evaluation of thrombin generation and emicizumab concentration in a cohort of severe Hemophilia A patients with and without inhibitor during emicizumab prophylaxis
-
Abstract Number: PB0798
Evaluation of thrombin generation capacity of plasma-derived Factor VIII/von Willebrand Factor in the Treatment of von Willebrand Disease
-
Abstract Number: VPB0119
Evaluation of thrombotic outcomes in patients in a large clinical enterprise following COVID-19 vaccination
-
Abstract Number: PB0828
Evaluation of within-subject variation of VWF multimers assay
-
Abstract Number: PB0399
Evidence for a PI3-kinase independent pathway in the regulation of Rap1b activation downstream of the P2Y12 receptor in platelets
-
Abstract Number: PB1263
Evidence for mitochondrial dysfunction in blood-derived endothelial colony forming cells isolated from patients with antiphospholipid syndrome
-
Abstract Number: PB0891
Evolution of the Platelet Plug and Leukocyte Recruitment After Initial Hemostasis In Vivo
-
Abstract Number: PB0536
Ex vivo study of the concomitant use of plasma-derived Factor VIII/Von Willebrand Factor and emicizumab in patients with severe Hemophilia A
-
Abstract Number: PB1215
Exacerbation of Immune Thrombocytopenia Following Initial and Booster Vaccination with Pfizer-BioNTech COVID-19 Vaccine
-
Abstract Number: PB1064
Exclusion of relevant concentrations of direct oral anticoagulants in blood by DOAC Dipstick – proposal of a diagnostic algorithm for improvement of clinical decision-making in emergencies
-
Abstract Number: VPB0131
Exogenous estrogen use for contraception and hormone replacement therapy and the risk of thrombosis in women with COVID-19
-
Abstract Number: VPB0317
Experience in Diagnosis and Treatment of Thrombotic Thrombocytopenic Purpura – Case Reports
-
Abstract Number: PB1129
Experience in rural areas in the evaluation of the joint health status of patients with non-severe hemophilia A not treated with prophylaxis.
-
Abstract Number: PB0440
Experience of Therapeutic Drug Monitoring in Patients Prescribed Direct Oral Anticoagulants (DOACs) of Low Body Weight ( < 55kg) at Guy’s & St Thomas’ NHS Foundation Trust
-
Abstract Number: VPB1018
Experience with the administration of Idarucizumab as a specific antagonist of Dabigatran in the emergency medicine
-
Abstract Number: PB1011
Experience with the use of 4-factor prothrombin complex concentrates for warfarin reversal in patients with a left ventricular assist device undergoing heart transplant.
-
Abstract Number: PB0528
Experimental investigation of the antiplatelet effect of Zingiber officinale (Ginger) ex vivo and in vitro
-
Abstract Number: VPB0527
Experimental model of rodent disseminated intravascular coagulation
-
Abstract Number: PB0715
Exploring diverse coagulation Factor XIII subunit expression datasets: A bioinformatic analysis
-
Abstract Number: OC 78.5
Exploring hidden bleeding phenotypes by screening FXIII and Fibrinogen genes
-
Abstract Number: PB0369
Exploring Platelet Proteins Altered in Severe COVID-19 Using Gene Ontology (GO) Pathways
-
Abstract Number: PB0185
Exploring red blood cells as a novel tolerogenic approach for factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II
-
Abstract Number: OC 07.4
Exploring the conformational landscape of Factor VIII B domain in order to generate an all atom full length structure of the coagulation Factor VIII protein
-
Abstract Number: PB0156
Expression of Exogenous Proteins in Donor Platelets Treated with Lipid Nanoparticles Encapsulating mRNA
-
Abstract Number: PB0094
Expression of extracellular vesicles in plasma and cerebrospinal fluid is associated with the procoagulant state in patients with neurological complications of COVID-19
-
Abstract Number: PB0144
Expression of microRNAs related to platelet function and cardiovascular events in patients with stable coronary artery disease
-
Abstract Number: PB0713
Extensive Genetic Screening of Iranian FVII deficient Individuals with severe phenotype unraveled Several Novel Mutations
-
Abstract Number: PB0261
Extensive thrombosis from cranial venous sinuses to superior vena cava in an infant with Lemierre syndrome with successful management
-
Abstract Number: OC 16.1
External validation of the Khorana and Vienna-CATS nomogram scores in cancer patients of the HYPERCAN cohort
-
Abstract Number: OC 31.2
External validation of the PEGeD diagnostic algorithm for suspected pulmonary embolism in an independent cohort
-
Abstract Number: PB0543
Extracellular vesicles from human body fluids trigger coagulation directly by exposing functional tissue factor/factor VIIa complexes
-
Abstract Number: VPB0519
Extracellular vesicles number and cell subtype may be influenced by diabetes mellitus and metformin in patients at high cardiovascular risk
-
Abstract Number: PB1028
Extracellular vesicles of activated platelets possess shifted lipid-rich biomolecular profile and display an increased procoagulant activity
-
Abstract Number: PB0014
Extreme Long-term Stability of Aspirin Tablets and Their Ability to Inhibit Platelet Aggregation
ISTH 2022 Congress
July 9-13, 2022. London, England, UK.